Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

78.96 +1.27 (+1.63%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,372,304
Open 78.62
Bid (Size) 74.25 (5)
Ask (Size) 78.95 (30)
Prev. Close 77.69
Today's Range 78.12 - 79.00
52wk Range 53.22 - 79.00
Shares Outstanding 2,222,113,553
Dividend Yield 2.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
From Bristol Myers Squibb
Via Business Wire
This Is What Whales Are Betting On Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga

Performance

YTD
+27.60%
+27.60%
1 Month
+2.23%
+2.23%
3 Month
+7.75%
+7.75%
6 Month
+26.76%
+26.76%
1 Year
+19.91%
+19.91%

More News

Read More
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
Via Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
From Bristol Myers Squibb
Via Business Wire
The 5 Top Profit & Protection Stocks to Buy for 2022
Via InvestorPlace
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
From Bristol Myers Squibb
Via Business Wire
Cisco And 2 Other Stocks Insiders Are Selling
Via Benzinga
As Health Problems Mount Patients Welcome New Treatments
Via FinancialNewsMedia
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
7 Blue-Chip Stocks With Strong Dividend Yields
Via InvestorPlace
SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
Via Benzinga
Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Whale Trades Spotted
Via Benzinga
7 Cheap Growth Stocks That Won’t Stay That Way for Long
Via InvestorPlace
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Via InvestorPlace
Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.